Michel Vounatsos, CEO, Biogen
As a new decade dawns, some of the world’s biggest companies are setting some big goals. Biogen is one of them… the Fortune 500 biotech firm is pushing for F-D-A approval of its new Alzheimer’s drug called “Aducanumab” (ah-doo-KHAN-a-mahb). If approved – it would be the FIRST drug that actually slows or reverses the mental decline caused by the deadly disease. It’s a daunting goal that many other pharma companies have given up on.